WPG Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

WPG Advisers’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$201	–	1551
2026 Q1	$201	Hold	5	–	–	﹤0.01%	1436
2025 Q4	$126	Hold	5	–	–	﹤0.01%	1458
2025 Q3	$113	Hold	5	–	–	﹤0.01%	1429
2025 Q2	$87	Hold	5	–	–	﹤0.01%	1418
2025 Q1	$109	Hold	5	–	–	﹤0.01%	1416
2024 Q4	$160	Buy	+5	New	+$150	﹤0.01%	1439

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

WPG Advisers's APLS Position: Q2 2026 in Review

WPG Advisers sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 5 shares — an estimated $201 sold.

WPG Advisers first reported a position in APLS in Q4 2024 and held it in 6 quarters. The position peaked at $201 in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

WPG Advisers reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
WPG Advisers sold 5 Apellis Pharmaceuticals shares in Q2 2026, an estimated $201.
WPG Advisers first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
WPG Advisers's Apellis Pharmaceuticals position peaked at $201 in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.